drugset / Trial / NCT06910098

Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

NCT06910098

Completed 195 enrolled Central Park Medical College
RandomizedParallel-groupDouble-blindPrevention

Summary

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Timeline

Start
2023-12-01
Primary completion
2024-06-30
Completion
2024-08-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rosuvastatin Small molecule 5 mg
Comparator Rosuvastatin Small molecule 10 mg
Comparator Rosuvastatin Small molecule 20 mg